[¹⁷⁷Lu]Lu-PSMA-617 was approved by the U.S. Food and Drug Administration for patients with prostate-specific membrane antigen (PSMA)–positive metastatic castration-resistant prostate cancer (mCRPC). Since the time of regulatory approval, however, real-world data have been lacking. This study investigated the efficacy, safety, and outcome predictors of [¹⁷⁷Lu]Lu-PSMA-617 at a major U.S. academic center. Methods: Patients with mCRPC who received [¹⁷⁷Lu]Lu-PSMA-617 at the Johns Hopkins Hospital outside clinical trials were screened for inclusion. Patients who underwent [¹⁷⁷Lu]Lu-PSMA-617 and had available outcome data were included in this study. Outcome data included prostate-specific antigen (PSA) response (≥50% decline), PSA progression-free survival (PFS), and overall survival (OS). Toxicity data were evaluated according to the Common Terminology Criteria for Adverse Events version 5.03. The study tested the association of baseline circulating tumor DNA mutational status in homologous recombination repair, PI3K alteration pathway, and aggressive-variant prostate cancer–associated genes with treatment outcome. Baseline PSMA PET/CT images were analyzed using SelectPSMA, an artificial intelligence algorithm, to predict treatment outcome. Associations with the observed treatment outcome were evaluated. Results: All 76 patients with PSMA-positive mCRPC who received [¹⁷⁷Lu]Lu-PSMA-617 met the inclusion criteria. A PSA response was achieved in 30 of 74 (41%) patients. The median PSA PFS was 4.1 mo (95% CI, 2.0–6.2 mo), and the median OS was 13.7 mo (95% CI, 11.3–16.1 mo). Anemia of grade 3 or greater, thrombocytopenia, and neutropenia were observed in 9 (12%), 3 (4%), and 1 (1%), respectively, of 76 patients. Transient xerostomia was observed in 23 (28%) patients. The presence of aggressive-variant prostate cancer–associated genes was associated with a shorter PSA PFS (median, 1.3 vs. 6.3 mo; P = 0.040). No other associations were observed between circulating tumor DNA mutational status and treatment outcomes. Eighteen of 71 (25%) patients classified by SelectPSMA as nonresponders had significantly lower rates of PSA response than patients classified as likely responders (6% vs. 51%; P < 0.001), a shorter PSA PFS (median, 1.3 vs. 6.3 mo; P < 0.001), and a shorter OS (median, 6.3 vs. 14.5 mo; P = 0.046). Conclusion: [¹⁷⁷Lu]Lu-PSMA-617 offered in a real-world setting after regulatory approval in the United States demonstrated antitumor activity and a favorable toxicity profile. Artificial-intelligence–based analysis of baseline PSMA PET/CT images may improve patient selection. Validation of these findings on larger cohorts is warranted.

Veterans are at an increased risk for prostate cancer, a disease with extraordinary clinical and molecular heterogeneity, compared with the general population. However, little is known about the underlying molecular heterogeneity within the veteran population and its impact on patient management and treatment. Using clinical and targeted tumor sequencing data from the National Veterans Affairs health system, we conducted a retrospective cohort study on 45 patients with advanced prostate cancer in the Veterans Precision Oncology Data Commons (VPODC), most of whom were metastatic castration-resistant. We characterized the mutational burden in this cohort and conducted unsupervised clustering analysis to stratify patients by molecular alterations. Veterans with prostate cancer exhibited a mutational landscape broadly similar to prior studies, including KMT2A and NOTCH1 mutations associated with neuroendocrine prostate cancer phenotype, previously reported to be enriched in veterans. We also identified several potential novel mutations in PTEN, MSH6, VHL, SMO, and ABL1. Hierarchical clustering analysis revealed two subgroups containing therapeutically targetable molecular features with novel mutational signatures distinct from those reported in the Catalogue of Somatic Mutations in Cancer database. The clustering approach presented in this study can potentially be used to clinically stratify patients based on their distinct mutational profiles and identify actionable somatic mutations for precision oncology.

The Cassini mission’s samples from Saturn’s moon Enceladus have signs of various organic molecules that could be among the ingredients needed for life to get started

Cases of prostate cancer are surging alarmingly around the world. Thankfully, we are developing more accurate tests that can catch the condition early

Not a surprising generational update, but a lot of progress for just one year.

Woman claims to have a degree from "Havard" and be licensed by the "Estate Board."

20,000 Australian men are diagnosed with prostate cancer every year. Research conducted by Prostate Cancer Foundation of Australia (PCFA), the Australian Research Centre in Sex, Health and Society, at La ...

The post Prostate Cancer is different for gay and bisexual men appeared first on Star Observer.

L’ex-maire, qui a passé cette année le cap des cinq ans depuis son diagnostic, continue de s’impliquer pour sensibiliser les hommes à ce fléau.

The way firms deal with fare evasion will be examined amid concern about how passengers are treated.

In this episode you can hear Olivia Friett, editor of Medical Plastics News talk to Erik Haines, managing director at Guidepoint Qsight where we will discuss Qsight Prospector, a data-driven sales intelligence programme.

Engineers at the University of British Columbia have collaborated with the Japanese automotive company Honda to develop an e-skin for robotic prostheses that allows such devices to sense their environment in significant detail. The soft skin is highly sensitive, letting robotic hands to perform tasks that require a significant degree of dexterity and tactile feedback, […]

Apr 11, 2024

On April 9, the study group met for the third time to examine economic development in Africa. The group explored connections between politics and economic growth trajectories across the continent, and analyzed the role of political instability and policy decisions in fostering development. Discussions covered the impact of factors like commodity markets, foreign aid, trade deals, and regional integration initiatives on development indicators. The study group counted with the presence of external expert guest H.E. Patrick Achi, former Prime Minister of Côte d’Ivoire. Prime Minister Achi shared about his experience at the highest level of government and presented the story of Côte d’Ivoire’s post-independence development as a microcosm of the broader challenges and opportunities facing African nations.

Qantas Wallabies player Nick Cummins promotes the #pass4prostate challenge and USA vs. Australia match coming up on Sept. 5 in Chicago. #pass4prostate and the match are presented by Astellas Pharma

Prostate Cancer Foundation, Evander Holyfield and Brian Custer encourage African-American men to �man up and get checked� for prostate cancer.

Know Your Stats� PSA

Highlights: The study compared prostate cancer mortality rate between subjects invited for a single invitation scre

Women take two types of pills for abortion during their pregnancy: medlinkmisoprostol/medlink, which causes the womb to contract, and medlinkmifepristone/medlink,

medlinkProstaglandin/medlink receptors are responsible for successful embryo implantation, and new research from Kumamoto University has revealed

Researchers have decoded how mutations in the CDK12 gene ignite prostate cancer and revealed a breakthrough treatment-a powerful degrader that targets

A groundbreaking study has revealed a promising new approach to prostate cancer treatment. The nanoparticle-based therapy, guided by laser technology,

The Pro-oxidant supplement menadione, a precursor to vitamin K, commonly found in leafy greens turns out to be a powerful weapon in the fight against prostate cancer.

The long-term risks of prostate cancer treatment, including adverse effects and complications, can persist for years. A recent study published in iJAMA

BDR Pharmaceuticals has launched novel prostate cancer drug named "Enzalutamide" in 160 mg strength. Under the brand name BDENZA 160mg, it has introduced

Men taking either abiraterone or enzalutamide for advanced prostate cancer who had also undergone hormone therapy were at increased risk of serious metabolic

Timely diagnosis and treatment can save men from developing enlarged prostates, reports a new study. Half of all men develop enlarged prostates - also

In men diagnosed with benign prostatic hyperplasia (BPH), the recently approved minimally invasive Optilume BPH device treatment not only enhances urinary

medlinkCancer/medlink-causing mutations in prostate cancer hyperactivate PI3K signaling, leading to cancer cell growth. PLEKHS1, a largely unknown

Dual treatment has improved the survival rates for men with metastatic prostate cancer by an average of six months. Dual treatment includes both standard

Decitabine, a medlinkprostate cancer/medlink drug, that inhibits DNA methylation, effectively cuts tumor growth in prostate cancer with neuroendocrine features or loss of the gene RB1.

New studies suggest that medlinkinflammation/medlink contributes to the onset of medlinkbenign prostatic hyperplasia/medlink (BPH), stemming from

New report outlines long-term risks of prostate cancer treatment, highlighting potential impacts on quality of life and need for informed decisions.

Covid-19 pandemic has increased the challenges and many patients have been neglected, especially the people affected by Leprosy. Reinforcing the need

A federal judge has agreed to Special Prosecutor Jack Smith's request to pause the election interference case against US President-elect Donald Trump in the first indication that cases against him are crumbling.

Australian CEOs are less confident about their companies' growth prospects than a year ago, and less optimistic about growth in the global economy, according to a PwC report released today.

Ever wondered how tennis pros are able to hit the ball with so much force, at extreme angles with incredible accuracy while still keeping it in the court? It comes down to physics. WSJ’s Daniela Hernandez explains what you can learn from the physics that give tennis pros their edge. Photo composite: Adele Morgan

Mike Waltz emphasises the significance of US-India ties for the 21st century, stating it will determine a century of light or darkness.

Cheltenham, UK ; Northampton, MA : Edward Elgar, [2011]

Successful implementation of FTAs, rupee trade, export schemes, PLI may provide relief

Trial run from Kochi to Mattupetty dam completed in 30 minutes. Tourism stakeholders say the service will be a game changer for a district that had no air connectivity hitherto

Talking to reporters in Gondia, Praful Patel said the allegations against Mr. Malik have not been proved in the court of law

Shyamala Miss’ class explores the variety of compositions by Saint Tyagaraja and what makes them special.

Stereotactic radiotherapy uses high doses of radiation to target and kill cancer cells; it uses newer machines that can deliver very focused radiation beams

Apple introduced two chips -the M1 Pro and the M1 Max in the new MacBook Pro 14 and 16-inch models

Samiya Parvez, along with her husband Naveed, co-founded medical device service startup Andiamo, which uses 3D printing to reduce wait times for custom orthoses for children with disabilities from six months down to one week. "The ingredients are all there," Parvez says of the current system. "But, you can't get to things fast enough and it's not gelled together." In this video, Parvez shares their startup's journey and how caring for their late son, Diamo, inspired his parents to develop a patient-centric, efficient and effective process for children with disabilities. ABOUT WIRED HEALTH 600 innovators, scientists and business leaders gathered at The Francis Crick Institute in London, for WIRED Health on March 26, 2019. Discover some of the fascinating insights from speakers here: http://wired.uk/health-event ABOUT WIRED EVENTS WIRED events shine a spotlight on the innovators, inventors and entrepreneurs who are changing our world for the better. Explore this channel for videos showing on-stage talks, behind-the-scenes action, exclusive interviews and performances from our roster of events. Join us as we uncover the most relevant, up-and-coming trends and meet the people building the future. ABOUT WIRED WIRED brings you the future as it happens - the people, the trends, the big ideas that will change our lives. An award-winning printed monthly and online publication. WIRED is an agenda-setting magazine offering brain food on a wide range of topics, from science, technology and business to pop-culture and politics. CONNECT WITH WIRED Events: http://wired.uk/events Subscribe for Events Information: http://wired.uk/signup Web: http://bit.ly/VideoWired Twitter: http://bit.ly/TwitterWired Facebook: http://bit.ly/FacebookWired Instagram: http://bit.ly/InstagramWired Magazine: http://bit.ly/MagazineWired Newsletter: http://bit.ly/NewslettersWired

Since the early 2000s, private companies, governments, and research labs have been developing prosthesis that are a lot more advanced than previous designs. WIRED talked with Easton LaChapelle, founder and CEO of Unlimited Tomorrow, to understand how he designed, tested, and adopted his prosthetic arm.The movie GENERATION IMPACT: THE INVENTOR, follows 25-year old innovator Easton LaChappelle, who developed the world’s lightest weight and most affordable bionic limb. GENERATION IMPACT: THE INVENTOR, can be viewed on HP.com’s digital hub, the Garage (hp.com/generation-impact) and YouTube

Professional prosthetic makeup artist Meg Wilbur explains special effects makeup in 11 levels of difficulty, from easy to complex. Special effects makeup is a really broad category, so Meg defines complexity as increasingly elaborate flourishes, texture and detail in her work. Meg goes over everything from temporary tattoos to prosthetic face applications and dry-brushing. MEG WILBUR: https://www.instagram.com/littlemonsterdoll/?hl=en BRITTANY TURPEN: https://www.instagram.com/brittanyyynicole/ ANDREW SCOTT MILLER: https://www.instagram.com/andrewscottmiller/ Director: Tim Cruz Director of Photography: Ricardo Pomares Editor: Louville Moore Talent: Meg Wilbur Producers: Adam Davis-McGee, Katherine Wzorek Line Producer: Joseph Buscemi Associate Producer: Melissa Cho Production Managers: Peter Brunette, Andressa Pelachi Production Coordinator: Carol Wachockier Set Decorator: Leah Waters-Katz Audio: Paul Cornett Cam Op/Gaffer: Nick Massey Production Assistants: Phillip Arliss, Devin Beckwith, Ariel Labasan Post Production Supervisor: Alexa Deutsch Post Production Coordinator: Ian Bryant Supervising Editor: Doug Larsen Assistant Editor: Diego Rentsch Special Thanks: Meg's Assistant Brittany Turpen, model Andrew Miller